Hopefully dosing starts soon and it will be open label early read outs, if that's the case then definitely all eyes will be on ANP and the big pharmas will be desperate to make an offer to protect their slice of income as ANP will definitely compliment their own treatment and go hand in hand.
Time will tell but happy to accept a takeover offer of $2+, thats loose change of a big pharama company.
Sarepta gene therapy study missed key target in Duchennes, page-88
-
- There are more pages in this discussion • 326 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
